Oral bisphosphonates and oesophageal cancer

BMJ (Online)

Volumn 341, Issue 7772, 2010, Pages 517-

  Wysowski, Diane K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; PAMIDRONIC ACID;

BARRETT ESOPHAGUS; CANCER RISK; COLORECTAL CANCER; DRUG WITHDRAWAL; DYSPHAGIA; EDITORIAL; ESOPHAGUS CANCER; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; ESOPHAGUS ULCER; EXUDATE; GRANULATION TISSUE; HUMAN; INCIDENCE; ODYNOPHAGIA; PRESCRIPTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH CANCER; THORAX PAIN;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; HUMANS; OSTEOPOROSIS;

EID: 77956545445     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4506     Document Type: Editorial

References (12)

1. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: nested case-control study. BMJ 2010;341:c4444. [Abstract/FREE Full text]
2. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994;4:320-2. [CrossRef] [Medline] [Web of Science]
3. Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-90. [Medline] [Web of Science]
4. Ribeiro A, DeVault KR, Wolfe JT III, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47:525-8. [CrossRef] [Medline] [Web of Science] (Pubitemid 28287574)
5. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu T-T. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999;12:1152-7. [Medline] [Web of Science] (Pubitemid 30033550)
6. Famularo G, De Simone C. Fatal esophageal perforation with alendronate. Am J Gastroenterol 2001;96:3212-3. [CrossRef] [Medline] [Web of Science]
7. Ryan JM, Kelsey P, Ryan BM, Mueller PR. Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture - radiographic features. Radiology 1998;206:389-91. [Abstract/FREE Full text] (Pubitemid 28112952)
8. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90. [FREE Full text]
9. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1789. [FREE Full text]
10. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:1789-90. [FREE Full text]
11. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63. [Abstract/FREE Full text]
12. Inderjeeth CA, Foo ACH, Lai MYM, Glendenning P. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 2009;44:744-51. [CrossRef] [Medline] [Web of Science]